bilirubin, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, bilirubin

Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E 1987 Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22: 655-664.
Abbasi S, Stewart DL, Radmacher P, Adamkin D 2008 Natural course of cholestasis in neonates on extracorporeal membrane oxygenation (ECMO): 10-year experience at a single institution. ASAIO J. 54: 436-438.
Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ 2008 Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47: 949-957. *
Abdel-Ghaffar YT, Amin E, Abdel-Rasheed M, Fouad HH 2003 Essential fatty acid status in infants and children with chronic liver disease. East. Mediterr. Health J. 9: 61-69.
Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura B, Hiasa Y, Horiike N 2007 Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 5: 255-258.
Abrams GA, Concato J, Fallon MB 1996 Muscle cramps in patients with cirrhosis. Am. J. Gastroenterol. 91: 1363-1366.
Abu-Elmagd KM, Malinchoc M, Dickson ER, Fung JJ, Murtaugh PA, Langworthy AL, Demetris AJ, Krom RA, Van Thiel DH, Starzl TE 1993 Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg. Gynecol. Obstet. 177: 335-344.
Aburano T 1995 Radionuclide imaging in hepatobiliary disease. Kaku Igaku 32: 599-603.
Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, Rubio Gonzalez EE, Rubio Gonzalez E, Boullosa Grana E, Sanchez-Turrion V, Sanz Guajardo D, Cuervas-Mons V 2005 Therapy of intractable pruritus with MARS. Transplant. Proc. 37: 1480-1481. *
Adachi Y, Kamisako T, Okuyama Y, Miya H 1996 Hepatic metabolism and transport of bilirubin and other organic anions. Nippon Rinsho 54: 2276-2290.
Adachi Y, Kobayashi Y 2005 Hepatic uptake of bilirubin re-visited. Hepatol. Res. 31: 193-194.
Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP 2005 Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 51: 1867-1873. *
Adams LA, Zein CO, Angulo P, Lindor KD 2004 A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 2365-2368. *
Adani GL, Lorenzin D, Curro G, Sainz-Barriga M, Comuzzi C, Bresadola V, Avellini C, Baccarani U 2007 Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction. Transplant. Proc. 39: 1904-1906. *
Aghai ZH, Mudduluru M, Nakhla TA, Amendolia B, Longo D, Kemble N, Kaki S, Sutsko R, Saslow JG, Stahl GE 2006 Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J. Perinatol. 26: 550-555.
Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, Coleman J, Lillemoe KD, Cameron JL 1998 Primary sclerosing cholangitis: resect, dilate, or transplant? Ann. Surg. 227: 412-423. *
Ai T, Azemoto R, Saisho H 2003 Prevention of gallstones by ursodeoxycholic acid after cardiac surgery. J. Gastroenterol. 38: 1071-1076. *
Akahoshi T, Hashizume M, Tanoue K, Morita M, Tomikawa M, Sugimachi K 2001 Hyperbilirubinemia induced by endoscopic variceal ligation for esophageal varices in a patient with primary biliary cirrhosis: a case report. Hepatogastroenterology 48: 1659-1661.
Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian S, Wright H, Nour B, Sebastian A 2006 The effect of total plasma exchange on fulminant hepatic failure. J. Clin. Apher. 21: 96-99.
Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y 2001 Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim. Biophys. Acta 1511: 7-16. *
Akita H, Suzuki H, Sugiyama Y 2002 Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3. Biochem. Biophys. Res. Commun. 299: 681-687. *
Akoume MY, Perwaiz S, Yousef IM, Plaa GL 2003 Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats. Toxicol. Sci. 73: 378-385. *
Akoume MY, Tuchweber B, Plaa GL, Yousef IM 2004 The role of mdr2 in manganese-bilirubin induced cholestasis in mice. Toxicol. Lett. 148: 41-51. *
Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A 2006 Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med. J. 47: 147-151. *
Aladag M, Gurakar A, Jalil S, Wright H, Alamian S, Rashwan S, Sebastian A, Nour B 2004 A liver transplant center experience with liver dialysis in the management of patients with fulminant hepatic failure: a preliminary report. Transplant. Proc. 36: 203-205. *
Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM 2005 A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J. Hepatol. 43: 990-996. *
Aldemir M, Faruk Gey I K M, Faruk Kokoglu O, Buyukbayram HI, Hosoglu SI, Yagmur Y 2003 Effects of ursodeoxycholic acid, glutamine and polyclonal immunoglobulins on bacterial translocation in common bile duct ligated rats. ANZ J. Surg. 73: 722-726. *
Aleryani SL, Cluette-Brown JE, Khan ZA, Hasaba H, Lopez de Heredia L, Laposata M 2005 Fatty acid methyl esters are detectable in the plasma and their presence correlates with liver dysfunction. Clin. Chim. Acta 359: 141-149. *
Alfter K, von Kugelgen I, Haenisch B, Frieling T, Hulsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ 2008 New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. Jul 23 [Epub ahead of print]. *
Alizadeh BZ, Njajou OT, Houwing-Duistermaat JJ, Jong Gd G, Vergeer JM, Hofman A, Pols HA, Duijn CM 2004 Does bilirubin protect against hemochromatosis gene (HFE) related mortality? Am. J. Med. Genet. 129A: 39-43. *
Almasio P, Bortolini M, Pagliaro L, Coltorti M 1990 Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 40 Suppl. 3: 111-123.
Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxi A 2000 Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment. Pharmacol. Ther. 14: 1645-1652. *
Alnounou M, Munoz SJ 2006 Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100. *
Alonso L AG 2006 Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann. Hepatol. 5: 184-186. *
Alvaro D, Piat C, Francia C, Franchitto A, Furfaro S, Valente C, Capocaccia L, Gaudio E 1996 Ultrastructural features of danazol-induced cholestasis: a case study. Ultrastruct. Pathol. 20: 491-495.
Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M 2008 A critical role for matrix metalloproteinases in liver regeneration. J. Surg. Res. 145: 192-198. *
Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG 1985 The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J. Clin. Apheresis 2: 219-223.
Ambrosino G, Naso A, Feltracco P, Carraro P, Basso SM, Varotto S, Cillo U, Zanus 2003 Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS). Acta Biomed. Ateneo Parmense 74 Suppl. 2: 7-9.
American Gastroenterological Association 2002 American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 123: 1364-1366. *
An Y, Xiao YB 2007 Growth hormone prevents acute liver injury induced by cardiopulmonary bypass in a rat model. J. Thorac. Cardiovasc. Surg. 134: 342-350.
Anand AC, Elias E, Neuberger JM 1996 End-stage primary biliary cirrhosis in a first generation migrant south Asian population. Eur. J. Gastroenterol. Hepatol. 8: 663-666.
Andersen S, Okkels H, Krarup H, Laurberg P 2006 Geographical clustering and maintained health in individuals harbouring the mutation for Greenland familial cholestasis: a population-based study. Scand. J. Gastroenterol. 41: 445-450. *
Anderson KE, Simionatto CS, Drummond GS, Kappas A 1986 Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans. Clin. Pharmacol. Ther. 39: 510-520.
Andrei VE, Schein M, Margolis M, Rucinski JC, Wise L 1998 Liver enzymes are commonly elevated following laparoscopic cholecystectomy: is elevated intra-abdominal pressure the cause? Dig. Surg. 15: 256-259.
Andrieu T, Thibault V, Malet I, Laporte J, Bauvois B, Agut H, Cahour A 2003 Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J. Clin. Virol. 27: 59-68.
Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M 2003 Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52: 879-885. *
Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD 2000 Oral budesonide in the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2333-2337. *
Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, Anderson ML, Mahoney DW, Lindor KD 1999 Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J. Hepatol. 30: 830-835. *
Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD 2000 Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31: 318-323. *
Angulo P, Jorgensen RA, Kowdley KV, Lindor KD 2008 Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig. Dis. Sci. 53: 1716-1720. *
Angulo P, Jorgensen RA, Lindor KD 2001 Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am. J. Gastroenterol. 96: 3152-3157. *
Angulo P, Lindor KD 1999 Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570. *
Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD 2000 Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32: 897-900. *
Anselmi M, Acuna JC, Del Valle A, Gemmato AM 2006 Endoscopic biliary stents for the temporary management of choledocholithiasis. Rev. Med. Chil. 134: 721-725.
Antonio Olivera M, Zapata L, Kaplan M, Bobadilla J, Corte G, de la Mora G, Uribe M, Cabiedes J, Dehesa M, Kershenobich D 1993 Prevalence of antinuclear antibodies in primary biliary cirrhosis, with negative antimitochondrial antibodies. Rev. Gastroenterol. Mex. 58: 220-222.
Aoki A, Kirino Y, Ishigatsubo Y, Senuma A, Nagaoka S 2004 Liver involvement in primary Sjogren's syndrome. Nihon Rinsho Meneki Gakkai Kaishi 27: 397-401.
Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, Kirimlioglu V, Yilmaz S 2005 Protective effect of resveratrol against oxidative stress in cholestasis. J. Surg. Res. 127: 112-117. *
Arakawa Y, Amaki S, Miyakawa H, Sakai T, Gotou I, Tanaka N, Moriyama M, Iwasaki A, Sugitani M, Arakawa Y 2004 PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J. Gastroenterol. 39: 490-495. *
Arulventhan R, Larcos G, Gruenewald S, Farrell G 2006 Primary sclerosing cholangitis: correlation of hepatobiliary scintigraphy with clinical and laboratory status. Australas. Radiol. 50: 330-334.
Ashamiss F, Wierzbicki Z, Chrzanowska A, Scibior D, Pacholczyk M, Kosieradzki M, Lagiewska B, Porembska Z, Rowinski W 2004 Clinical significance of arginase after liver transplantation. Ann. Transplant. 9: 58-60.
Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ 2003 Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J. Lab. Clin. Med. 142: 385-390. *
Aspirot A, Su W, Flageole H, Puligandla PS, Shaw K, Laberge JM 2007 Cholestasis associated with small bowel atresia: do we always need to investigate? J. Pediatr. Surg. 42: 873-877.
Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, Pascussi JM 2004 Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 40: 951-960. *
Attie AD, Flowers MT, Flowers JB, Groen AK, Kuipers F, Ntambi JM 2007 Stearoyl-CoA desaturase deficiency, hypercholesterolaemia, cholestasis and diabetes. Novartis Found. Symp. 286: 47-53.
Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballauff A, Wallot M, Borchers T, Vester U, Grasemann C, Hauffa B, Hoyer PF, Gerken G, Voit T 2005 Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J. Pediatr. Gastroenterol. Nutr. 40: 54-59. *
Avezov SA, Mansurov FKh 2004 Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 55-58.
Avezov SA, Mansurova FKh 2004 Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 46-49.
Aviles J, Macia M, Morales S, Perez F, Moreno A, Navarro J, Navazo L, Garcia J 2001 Efficiency of dialysis with albumin in the treatment of patients with advanced hepatic insufficiency: initial experience with the MARS system in Spain. Nefrologia 21: 376-385.
AydoGdu S, Ozgenc F, AtIk T, Unal F, Tokat Y, Yagci RV 2004 Biliary atresia in Turkish children. Pediatr. Int. 46: 158-161. *
Aydogdu S, Ozgenc F, Yurtsever S, Akman SA, Tokat Y, Yagci RV 2003 Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J. Trop. Pediatr. 49: 367-370. *
Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S 2007 Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410. *
Azarpira N, Ramzi M, Aghdaie MH, Daraie M, Geramizadeh B 2007 Methylenetetrahydrofolate reductase C677T genotypes and clinical outcome following hematopoietic cell transplant. Exp. Clin. Transplant. 5: 693-697.
Azer SA 2005 A multimedia CD-ROM tool to improve student understanding of bile salts and bilirubin metabolism: evaluation of its use in a medical hybrid PBL course. Adv. Physiol. Educ. 29: 40-50. *
Azer SA, Canfield PJ, Stacey NH 1995 Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. J. Gastroenterol. Hepatol. 10: 261-269.
Azer SA, Coverdale SA, Byth K, Farrell GC, Stacey NH 1996 Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease. J. Gastroenterol. Hepatol. 11: 208-215.
Azzaroli F, Mennone A, Feletti V, Simoni P, Baglivo E, Montagnani M, Rizzo N, Pelusi G, DE Aloysio D, Lodato F, Festi D, Colecchia A, Roda E, Boyer JL, Mazzella G 2007 Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment. Pharmacol. Ther. 26: 1139-1146. *
Bachs L, Pares A, Elena M, Piera C, Rodes J 1992 Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080.
Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M 2008 Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 28: 948-958. *
Bagur A, Mautalen C, Findor J, Sorda J, Somoza J 1998 Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif. Tissue Int. 63: 385-390. *
Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH 1993 Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18: 1392-1398.
Balan V, Dickson ER, Jorgensen RA, Lindor KD 1994 Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin. Proc. 69: 923-929.
Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER 1990 Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 98: 1567-1571.
Baliga P, Alvarez S, Lindblad A, Zeng L 2004 Posttransplant survival in pediatric fulminant hepatic failure: the SPLIT experience. Liver Transpl. 10: 1364-1371. *
Balistreri WF 2003 Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Balistreri WF 1997 Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589.
Balladur P, de Hemptinne B, Geubel A, Rahier J, Reynaert M, De Kock M, Carlier MA, Otte JB 1990 Hepatic transplantation in cirrhosis. Acta Gastroenterol. Belg. 53: 267-275.
Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N 2001 Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest. Endosc. 53: 308-312. *
Bambha KM, Biggins SW 2008 Inequities of the model for end-stage liver disease: an examination of current components and future additions. Curr. Opin. Organ Transplant. 13: 227-233.
Barcena R, Moreno A, Foruny JR, Moreno A, Sanchez J, Gil-Grande L, Blazquez J, Nuno J, Fortun J, Rodriguez-Gandia MA, Oton E 2006 Improved graft function in liver-transplanted patients after partial splenic embolization: reversal of splenic artery steal syndrome? Clin. Transplant. 20: 517-523. *
Bardia A, Thompson CA, Podratz KC, Okuno SH 2007 Bizarre big belly ball: intraabdominal abscess mimicking Stauffer syndrome secondary to uterine leiomyosarcoma. Eur. J. Gynaecol. Oncol. 28: 134-136.
Barnes DS 2002 Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
Barton SG, Rampton DS, Winrow VR, Domizio P, Feakins RM 2003 Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. Cell Stress Chaperones 8: 329-334. *
Barve A, Khan R, Marsano L, Ravindra KV, McClain C 2008 Treatment of alcoholic liver disease. Ann. Hepatol. 7: 5-15. *
Basarir Ozkan T, Mistik R, Dikici B, Ozturk Nazlioglu H 2007 Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis. BMC Gastroenterol. 7: 9. *
Bassendine MF, Dewar PJ, James OF 1985 HLA-DR antigens in primary biliary cirrhosis: lack of association. Gut 26: 625-628. *
Batra Y, Acharya SK 2003 Acute liver failure: prognostic markers. Indian J. Gastroenterol. 22 Suppl. 2: S66-S68.
Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, Pagliaro L, Manenti F 1993 Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J. Hepatol. 17: 332-338.
Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, Villa E, Podda M 2001 Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment. Pharmacol. Ther. 15: 1427-1434. *
Batts KP, Jorgensen RA, Dickson ER, Lindor KD 1996 Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 91: 2314-2317.
Baur G, Schwalbach G, Tittor W 1982 New aspects of the pathogenesis of primary biliary cirrhosis, a study of 42 patients. Dtsch. Med. Wochenschr. 107: 378-382.
Beau P, Barrioz T, Ingrand P 1994 Total parenteral nutrition-related cholestatic hepatopathy, is it an infectious disease? Gastroenterol. Clin. Biol. 18: 63-67.
Beau P, Labat-Labourdette J, Ingrand P, Beauchant M 1994 Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J. Hepatol. 20: 240-244.
Beckebaum S, Cicinnati V, Broelsch CE 2003 Liver transplantation, rejection and disease recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 55-56. October 15-16. *
Beissert M, Wittenberg G, Sandstede J, Beer M, Tschammler A, Burghardt W, Jahns R, Hahn D 2002 Metallic stents and plastic endoprostheses in percutaneous treatment of biliary obstruction. Z. Gastroenterol. 40: 503-510.
Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, Klein-Szanto A, Lerro A, Kruh GD 2005 Analysis of the in vivo functions of Mrp3. Mol. Pharmacol. 68: 160-168. *
Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, Joannidis M 2004 Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl. 10: 107-114. *
Bellodi-Privato M, Aubert D, Pichard V, Myara A, Trivin F, Ferry N 2005 Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors. Hepatology 42: 431-438. *
Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, Burroughs A 1997 Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J. Hepatol. 26: 554-559. *
Ben-Ari Z, Schmilovotz-Weiss H, Belinki A, Pappo O, Sulkes J, Neuman MG, Kaganovsky E, Kfir B, Tur-Kaspa R, Klein T 2003 Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J. Intern. Med. 254: 168-175. *
Ben-Ari Z, Weiss-Schmilovitz H, Sulkes J, Brown M, Bar-Nathan N, Shaharabani E, Yussim A, Shapira Z, Tur-Kaspa R, Mor E 2004 Serum cholestasis markers as predictors of early outcome after liver transplantation. Clin. Transplant. 18: 130-136.
Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM 2008 Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J. Clin. Gastroenterol. 42: 306-311.
Bengoa JM, Hanauer SB, Sitrin MD, Baker AL, Rosenberg IH 1985 Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology 5: 79-84.
Beorchia S, Vincent C, Revillard JP, Trepo C 1981 Elevation of serum beta 2 microglobulin in liver diseases. Clin. Chim. Acta 109: 245-255.
Berber E, Rogers S, Siperstein A 2005 Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer. A prospective study. Surg. Endosc. 19: 710-714. *
Berberat PO, A-Rahim YI, Yamashita K, Warny MM, Csizmadia E, Robson SC, Bach FH 2005 Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm. Bowel Dis. 11: 350-359. *
Bergasa NV 2005 The pruritus of cholestasis. J. Hepatol. 43: 1078-1088. *
Bergasa NV, Jones A, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH 1996 Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am. J. Gastroenterol. 91: 295-299.
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *
Bertolami MC 2005 Mechanisms of hepatotoxicity. Arq. Bras. Cardiol. 85 Suppl. 4: 25-27.
Bertrams A, Ziegler K 1991 Hepatocellular uptake of peptides by bile acid transporters: relationship of carrier-mediated transport of linear peptides with renin-inhibiting activity to multispecific bile acid carriers. Biochim. Biophys. Acta 1091: 337-348.
Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G 1992 Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16: 707-714.
Beuers U, Spengler U, Sackmann M, Paumgartner G, Sauerbruch T 1992 Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis. J. Hepatol. 15: 140-143.
Beukers R, van Zanten RA, Schalm SW 1992 Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis. J. Hepatol. 14: 22-29.
Bhan AK, Dienstag JL, Wands JR, Schlossman SF, Reinherz EL 1982 Alterations of T-cell subsets in primary biliary cirrhosis. Clin. Exp. Immunol. 47: 351-358. *
Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD 2000 A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2338-2342. *
Binder G, Martin DD, Kanther I, Schwarze CP, Ranke MB 2007 The course of neonatal cholestasis in congenital combined pituitary hormone deficiency. J. Pediatr. Endocrinol. Metab. 20: 695-702.
Binder T, Zima T, V�tek L 2007 Biochemical parameters of the intrahepatic cholestasis of pregnancy. Ceska. Gynekol. 72: 90-94.
Bittencourt PL, Farias AQ, Abrantes-Lemos CP, Goncalves LL, Goncalves PL, Magalhaes EP, Carrilho FJ, Laudanna AA, Cancado EL 2004 Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 19: 873-878. *
Bjornsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R 2007 Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment. Pharmacol. Ther. 26: 79-85. *
Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R 2004 Dominant strictures in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 99: 502-508. *
Bjornsson E, Nordlinder H, Olsson R 2006 Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44: 791-797. *
Bjornsson E, Olsson R 2005 Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42: 481-489. *
Bjornsson E, Simren M, Olsson R, Chapman RW 2005 Fatigue is not a specific symptom in patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 17: 351-357.
Blann AD, Babbs C, Neuberger JM 1992 Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms. Clin. Exp. Immunol. 90: 88-92. *
Blasco A, Dominguez P, Colina F, Castellano G 1992 Wilson's disease. A histological review of 7 patients and the value of histological copper positivity in relation to other hepatopathies. Med. Clin. (Barc.) 98: 207-211.
Blaszyk H, Wild PJ, Oliveira A, Kelly DG, Burgart LJ 2005 Hepatic copper in patients receiving long-term total parenteral nutrition. J. Clin. Gastroenterol. 39: 318-320.
Blau J, Sridhar S, Mathieson S, Chawla A 2007 Effects of protein/nonprotein caloric intake on parenteral nutrition associated cholestasis in premature infants weighing 600-1000 grams. JPEN J. Parenter. Enteral Nutr. 31: 487-490.
Blazovics A 2007 Gallstone disease: free radical reactions and the ambivalent role of bilirubin in the pathomechanism of gallstone formation. Orv. Hetil. 148: 589-596.
Blejter J, Weller S, Pace R, Cusumano H, Giambini D 2008 Autoimmune pancreatitis: an adolescent case and review of literature. J. Pediatr. Surg. 43: 1368-1372.
Bloomer JR, Allen RM, Klatskin G 1976 Serum bile acids in primary biliary cirrhosis. Arch. Intern. Med. 136: 57-61.
Bloomer JR, Boyer JL 1975 Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82: 310-317.
Boberg KM, Egeland T, Schrumpf E 2003 Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand. J. Gastroenterol. 38: 991-995. *
Boberg KM, Rocca G, Egeland T, Bergquist A, Broome U, Caballeria L, Chapman R, Hultcrantz R, Mitchell S, Pares A, Rosina F, Schrumpf E 2002 Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 35: 652-657. *
Boberg KM, Schrumpf E 2004 Prognosis of autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 81. *
Bock KW, Kohle C 2004 Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters. Drug Metab. Rev. 36: 595-615.
Bode KA, Donner MG, Leier I, Keppler D 2002 Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem. Pharmacol. 64: 151-158. *
Bodenheimer HC Jr, Schaffner F, Sternlieb I, Klion FM, Vernace S, Pezzullo J 1985 A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5: 1139-1142.
Boey JH, Way LW 1980 Acute cholangitis. Ann. Surg. 191: 264-270. *
Bogdanovic M, Bulat P 2008 Biliary function in workers occupationally exposed to aluminium dust and fumes. Arh. Hig. Rada. Toksikol. 59: 135-139.
Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE 1999 Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29: 39-43. *
Boone RH, Cheung AM, Girlan LM, Heathcote EJ 2006 Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig. Dis. Sci. 51: 1103-1112. *
Borini P, Guimaraes RC 2003 Noninvasive classification of liver disease in asymptomatic and oligosymptomatic male alcoholics. Braz. J. Med. Biol. Res. 36: 1367-1373. *
Borst P, de Wolf C, van de Wetering K 2007 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453: 661-673. *
Borst P, Evers R, Kool M, Wijnholds J 2000 A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92: 1295-1302. *
Bosma PJ 2003 Inherited disorders of bilirubin metabolism. J. Hepatol. 38: 107-117. *
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, et al 1995 The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333: 1171-1175. *
Bower RH 1983 Hepatic complications of parenteral nutrition. Semin. Liver Dis. 3: 216-224.
Boyer JL 2005 Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740. *
Boyer JL, Ng OC, Ananthanarayanan M, Hofmann AF, Schteingart CD, Hagenbuch B, Stieger B, Meier PJ 1994 Expression and characterization of a functional rat liver Na+ bile acid cotransport system in COS-7 cells. Am. J. Physiol. 266: G382-G387.
Braier J, Ciocca M, Latella A, de Davila MG, Drajer M, Imventarza O 2002 Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med. Pediatr. Oncol. 38: 178-182. *
Brandoni A, Anzai N, Kanai Y, Endou H, Torres AM 2006 Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat. The role of OAT1 and OAT3. Biochim. Biophys. Acta 1762: 673-682. *
Brandsaeter B, Broome U, Isoniemi H, Friman S, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Olsson R, Olausson M, Kirkegaard P, Bjoro K 2003 Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl. 9: 961-969. *
Brandsaeter B, Schrumpf E, Clausen OP, Abildgaard A, Hafsahl G, Bjoro K 2004 Recurrent sclerosing cholangitis or ischemic bile duct lesions - a diagnostic challenge? Liver Transpl. 10: 1073-1074. *
Bray GP, Williams R 1992 Immunointervention in primary biliary cirrhosis: an overview. J. Autoimmun. 5 Suppl. A: 293-300.
Bressler B, Pinto R, El-Ashry D, Heathcote EJ 2005 Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut 54: 407-410. *
Brites D 2002 Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann. Hepatol. 1: 20-28. *
Brito MA, Lima S, Fernandes A, Falcao AS, Silva RF, Butterfield DA, Brites D 2008 Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. Neurotoxicology 29: 259-269.
Briz O, Macias RI, Perez MJ, Serrano MA, Marin JJ 2006 Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290: R749-R756. *
Brodanova M, Perlik F 1997 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Cas. Lek. Cesk. 136: 215-220.
Broome U, Eriksson LS 1994 Assessment for liver transplantation in patients with primary sclerosing cholangitis. J. Hepatol. 20: 654-659.
Broome U, Eriksson LS, Sundin U, Sundqvist KG 1992 Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis patients. Scand. J. Gastroenterol. 27: 124-128.
Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G 1996 Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610-615. *
Bruix J 2003 Hepatocellular carcinoma. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 31-33. October 17 - 19. *
Budillon G 1993 The epidemiology of cholestasis in hepatopathies. Ann. Ital. Med. Int. 8: 36S-40S.
Bueno MR, Daneri A, Armendariz-Borunda J 2000 Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J. Hepatol. 33: 915-925. *
Bugeac N, Pacht A, Mandel H, Iancu T, Tamir A, Srugo I, Shaoul R 2007 The significance of isolated elevation of serum aminotransferases in infants and young children. Arch. Dis. Child. 92: 1109-1112.
Bugianesi E 2005 Late complications of NASH: a challenge for hepatologists. J. Hepatol. 42: 784-785.
Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S 1984 Bacteriuria and primary biliary cirrhosis. Gut 25: 133-137. *
Burton JR Jr, Rosen HR 2005 Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin. Gastroenterol. Hepatol. 3: 700-704.
Bush DA, Hillebrand DJ, Slater JM, Slater JD 2004 High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127 (5 Suppl. 2): S189-S193. *
Busuttil Naudi A, Ammari AB, Fung DE 2008 A report of 2 cases of green pigmentation in the primary dentition associated with cholestasis caused by sepsis. J. Dent. Child. (Chic.) 75: 91-94.
Buyukasik Y, Akman U, Buyukasik NS, Goker H, Kilicarslan A, Shorbagi AI, Hascelik G, Haznedaroglu IC 2008 Evidence for higher red blood cell mass in persons with unconjugated hyperbilirubinemia and Gilbert's syndrome. Am. J. Med. Sci. 335: 115-119.
Caballeria L, Pares A, Rodes J 1999 Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85. *
Cai W, Wu J, Hong L, Xu Y, Tang Q, Shi C 2006 Oxidative injury and hepatocyte apoptosis in total parenteral nutrition-associated liver dysfunction. J. Pediatr. Surg. 41: 1663-1668.
Calabrese V, Butterfield DA, Stella AM 2003 Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. Ital. J. Biochem. 52: 177-181.
Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA 2005 Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233: 145-162. *
Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA 2003 Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25: 437-444. *
Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F 2005 A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42: 1373-1381. *
Calmus Y, Poupon R 1991 Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 73: 1335-1338.
Cameron JL, Gayler BW, Herlong HF, Maddrey WC 1983 Sclerosing cholangitis: biliary reconstruction with silastic transhepatic stents. Surgery 94: 324-330.
Cameron JL, Gayler BW, Sanfey H, Milligan F, Kaufman S, Maddrey WC, Herlong HF 1984 Sclerosing cholangitis. Anatomical distribution of obstructive lesions. Ann. Surg. 200: 54-60. *
Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA 1998 Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am. J. Gastroenterol. 93: 1510-1517. *
Cangemi JR, Wiesner RH, Beaver SJ, Ludwig J, MacCarty RL, Dozois RR, Zinsmeister AR, LaRusso NF 1989 Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96: 790-794.
Caponcelli E, Knisely AS, Davenport M 2008 Cystic biliary atresia: an etiologic and prognostic subgroup. J. Pediatr. Surg. 43: 1619-1624.
Cappell MS 2006 The effect of Nazism on medical progress in gastroenterology: the inefficiency of evil. Dig. Dis. Sci. 51: 1137-1158. *
Cardona J, Houssin D, Gauthier F, Devictor D, Losay J, Hadchouel M, Bernard O 1995 Liver transplantation in children with Alagille syndrome - a study of twelve cases. Transplantation 60: 339-342.
Carpenter SL, Lieff S, Howard TA, Eggleston B, Ware RE 2008 UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia. Am. J. Hematol. Aug 6 [Epub ahead of print]. *
Carter BA, Shulman RJ 2007 Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 277-287. *
Castro-e-Silva Junior O, Franco CF, Souza ME, Picinato MA, Santos JS, Ceneviva R 1990 Serum gamma-glutamyl transpeptidase in chronic extrahepatic cholestasis. Braz. J. Med. Biol. Res. 23: 515-518.
Cathebras PJ, Mosnier JF, Gouilloud S, Bouchou K, Rousset H 1995 Hepatic granulomatosis in a patient with Graves' disease. Eur. J. Gastroenterol. Hepatol. 7: 905-908.
Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ 1998 Fatigue in primary biliary cirrhosis. Gut 43: 705-710. *
Cebecauerova D, Jirasek T, Budisova L, Mandys V, Volf V, Novotna Z, Subhanova I, Hrebicek M, Elleder M, Jirsa M 2005 Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 129: 315-320. *
Chaar V, Keclard L, Etienne-Julan M, Diara JP, Elion J, Krishnamoorthy R, Romana M 2006 UGT1A1 polymorphism outweighs the modest effect of deletional (-3.7 kb) alpha-thalassemia on cholelithogenesis in sickle cell anemia. Am. J. Hematol. 81: 377-379. *
Chakurski I, Stefanov G, Belovezhdov N 1985 Acute allopurinol (milurit) poisoning. Vutr. Boles. 24: 136-139.
Chalasani N, Saha C, Teal E 2007 Are there ethnicity-based differences in the evaluation of individuals with abnormal liver biochemistries? J. Hepatol. 47: 123-127. *
Chan CW, Carpenter JR, Rigamonti C, Gunsar F, Burroughs AK 2005 Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model. Scand. J. Gastroenterol. 40: 1081-1089. *
Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK 2005 Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment. Pharmacol. Ther. 21: 217-226. *
Chan PC, Chen HL, Ni YH, Hsu HY, Chang LY, Lee PI, Chang MH 2004 Outcome predictors of fulminant hepatic failure in children. J. Formos. Med. Assoc. 103: 432-436.
Chang JL, Bigler J, Schwarz Y, Li SS, Li L, King IB, Potter JD, Lampe JW 2007 UGT1A1 polymorphism is associated with serum bilirubin concentrations in a randomized, controlled, fruit and vegetable feeding trial. J. Nutr. 137: 890-897. *
Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.
Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD 2007 Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27: 220-226. *
Chazouilleres O 2004 Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope? J. Hepatol. 40: 857-859. *
Chazouilleres O, Marteau P, Haniche M, Jian R, Poupon R 1996 Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA). Dig. Dis. Sci. 41: 2417-2422.
Chen C, Staudinger JL, Klaassen CD 2003 Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab. Dispos. 31: 908-915. *
Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH 2004 Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J. Pediatr. 145: 317-321. *
Chen HW, Chen HL, Ni YH, Lee NC, Chien YH, Hwu WL, Huang YT, Chiu PC, Chang MH 2008 Chubby face and the biochemical parameters for the early diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency. J. Pediatr. Gastroenterol. Nutr. 47: 187-192.
Chen J, Raymond K 2006 Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml).
Chen J, Terada T, Ogasawara K, Katsura T, Inui KI 2008 Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am. J. Physiol. Renal Physiol. 295: F247-F252. *
Chen TM, Subeq YM, Lee RP, Chiou TW, Hsu BG 2008 Single dose intravenous thioacetamide administration as a model of acute liver damage in rats. Int. J. Exp. Pathol. 89: 223-231.
Chen W, Cai SY, Xu S, Denson L, Soroka C, Boyer JL 2007 Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1221-G1227. *
Chen W, Gluud C 2003 Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD003626. *
Chen WD, Gluud C 2004 Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 3: CD004036. *
Chen YC, Huang LT, Wang SM, Tiao MM, Liu JW 2007 Acute hepatitis A infection in children: a 20-year experience of a medical center in Southern Taiwan. Acta Paediatr. Taiwan 48: 131-134.
Chen Z, Ding Y, Li G 2005 Configuration of a new bioartificial liver support system and in vitro evaluation of its functions. Ann. Clin. Lab. Sci. 35: 7-14.
Chernev K, Bakalov V 1985 Clinical-dispensary finding of patients with primary biliary cirrhosis. Vutr. Boles. 24: 42-46.
Chiarla C, Giovannini I, Siegel JH 2008 Patterns of correlation of plasma ceruloplasmin in sepsis. J. Surg. Res. 144: 107-110.
Chicharro M, Guarner L, Vilaseca J, Planas M, Malagelada J 2000 Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev. Esp. Enferm. Dig. 92: 68-77.
Chiu A, Chan LM, Fan ST 2006 Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int. 26: 695-702. *
Chiu A, Fan ST 2006 MARS in the treatment of liver failure: controversies and evidence. Int. J. Artif. Organs 29: 660-667.
Cho JY, Suh KS, Lee HW, Cho EH, Yang SH, Cho YB, Yi NJ, Kim MA, Jang JJ, Lee KU 2006 Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl. Int. 19: 807-813. *
Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ 2005 In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352.
Choi JY, Bae SH, Yoon SK, Cho SH, Yang JM, Han JY, Ahn BM, Chung KW, Sun HS, Kim DG 2005 Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation - a pilot study. Liver Int. 25: 740-745. *
Choi SJ, Gwak MS, Kim MH, Yang M, Ko JS, Hahm TS, Kim GS 2005 Differences of perioperative liver function, transfusion, and complications according to the type of hepatectomy in living donors. Transpl. Int. 18: 548-555. *
Choudhuri G, Somani SK, Baba CS, Alexander G 2005 Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterol. 5: 27. *
Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG 2008 Liver involvement in systemic lupus erythematosus: case review of 40 patients. J. Rheumatol. Sep 15 [Epub ahead of print].
Christensen E 2003 Prognosis of untreated primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 63. October 15-16. *
Christensen E, Altman DG, Neuberger J, De Stavola BL, Tygstrup N, Williams R 1993 Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology 105: 1865-1876.
Christensen E, Crowe J, Doniach D, Popper H, Ranek L, Rodes J, Tygstrup N, Williams R 1980 Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78: 236-246.
Christensen E, Gunson B, Neuberger J 1999 Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. J. Hepatol. 30: 285-292. *
Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R 1985 Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89: 1084-1091.
Chu X, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R 2006 Characterization of mice lacking the multidrug resistance protein Mrp2 (Abcc2). J. Pharmacol. Exp. Ther. 317: 579-589. *
Chung H, Kudo M, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y 2006 A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol. Res. 34: 124-129.
Church NI, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, Gillams A, Rodriguez-Justo M, Novelli M, Seward EW, Hatfield AR, Webster GJ 2007 Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am. J. Gastroenterol. 102: 2417-2425. *
Cicek D, Kandi B, Demir B, Turgut D 2007 Intrahepatic cholestasis occurring with prurigo of pregnancy. Skinmed. 6: 298-301.
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S 2007 Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol. 7: 44. *
Cole CR, Bucuvalas JC, Hornung RW, Krug S, Ryckman FC, Atherton H, Alonso MP, Balistreri WF, Kotagal U 2004 Impact of liver transplantation on HRQOL in children less than 5 years old. Pediatr. Transplant. 8: 222-227.
Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet JC, Ricour C 2000 Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J. Parenter. Enteral Nutr. 24: 345-350.
Colombo M, Sangiovanni A 2003 Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 60: 145-150. *
Coltorti M, Bortolini M, Di Padova C 1990 A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find. Exp. Clin. Pharmacol. 12: 69-78.
Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers Jr RL, Rosoff Jr L, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, et al 2005 Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42: 1184-1193. *
Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Munoz SJ, Rubin R, Garcia-Tsao G, et al 1995 A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22: 759-766.
Combes B, Luketic VA, Peters MG, Zetterman RK, Garcia-Tsao G, Munoz SJ, Lin D, Flye N, Carithers RL Jr 2004 Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am. J. Gastroenterol. 99: 264-268. *
Conseil G, Deeley RG, Cole SP 2005 Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 15: 523-533.
Cooper A, Betts JM, Pereira GR, Ziegler MM 1984 Taurine deficiency in the severe hepatic dysfunction complicating total parenteral nutrition. J. Pediatr. Surg. 19: 462-466.
Cornelius CE 1981 Hepatic bilirubin-IX-alpha-glycosyltransferase activities in animals excreting primarily biliverdin into bile. Vet. Clin. Pathol. 10: 27-31.
Cornelius CE, Bruss ML 1980 Hepatic bile pigment excretion and erythrocyte turnover in various species. Vet. Clin. Pathol. 9: 15-20.
Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, Chazouilleres O, Poupon R 2008 Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48: 871-877.
Corpechot C, Benlian P, Barbu V, Chazouilleres O, Poupon RE, Poupon R 2001 Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J. Hepatol. 35: 324-328. *
Corpechot C, Carrat F, Poupon R, Poupon RE 2002 Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 122: 652-658. *
Corpechot C, Ping C, Wendum D, Matsuda F, Barbu V, Poupon R 2006 Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am. J. Gastroenterol. 101: 2427-2432. *
Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chretien Y, Poupon RE, Poupon R 2004 Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 24: 187-193. *
Correa GH, Paredes SN 2007 Serum liver tests in patients treated with methotrexate: a retrospective analysis. Rev. Med. Chil. 135: 1002-1008.
Cosme A, Gil I, Alvarez R, Ruiz I, de Juan MD, Ojeda E, Barrio J 1998 Autoimmune hepatitis with antibodies against liver cytosol (anti-LC1). Gastroenterol. Hepatol. 21: 280-282.
Costa C, Sambataro A, Baldi S, Modena V, Todros L, Libertucci D, Coni F, Fusaro E, Revello F, Murgia A, et al 1995 Primary biliary cirrhosis: lung involvement. Liver 15: 196-201.
Costa DB, Miksad RA, Buff MS, Wang Y, Dezube BJ 2006 Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. J. Natl. Med. Assoc. 98: 1183-1187.
Coverdale SA, Field J, Farrell GC 2003 How reversible is hepatic functional impairment in autoimmune hepatitis? J. Gastroenterol. Hepatol. 18: 371-375. *
Cox KL, Cox KM 1998 Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583.
Cravetto C, Molino G, Biondi AM, Cavanna A, Avagnina P, Frediani S 1985 Evaluation of the diagnostic value of serum bile acid in the detection and functional assessment of liver diseases. Ann. Clin. Biochem. 22: 596-605.
Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, Sverzellati E, Tacchini G, Pierfranceschi MG, Carrara GC 1995 Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clin. Ter. 146: 367-372.
Crippin JS, Jorgensen RA, Dickson ER, Lindor KD 1994 Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am. J. Gastroenterol. 89: 47-50.
Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell KD 1991 Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 13: 1076-1083.
Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez T, Lopez S, Garsd A, Alvarez F 2006 Follow-up of children with autoimmune hepatitis treated with cyclosporine. J. Pediatr. Gastroenterol. Nutr. 43: 635-639. *
Cui Y, Konig J, Leier I, Buchholz U, Keppler D 2001 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276: 9626-9630. *
Cui Y, Konig J, Nies AT, Pfannschmidt M, Hergt M, Franke WW, Alt W, Moll R, Keppler D 2003 Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83: 527-538.
Culafic D, Perisic M, Boricic I, Culafic-Vojinovic V, Vukcevic M 2007 Primary amyloidosis presenting with cholestasis and hyperkinetic portal hypertension. J. Gastrointestin. Liver Dis. 16: 201-204. *
Cuomo R, Rodino S, Rizzoli R, Simoni P, Roda E, Cantoni L, Rizzardini M, De Rosa G, Le Grazie C, Di Padova C, et al 1991 Bile and biliary lipid secretion in rats with hexachlorobenzene-induced porphyria. Effect of S-adenosyl-L-methionine administration. J. Hepatol. 12: 87-93.
Cutillo L, Najimi M, Smets F, Janssen M, Reding R, de Goyet Jde V, Sokal EM 2006 Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis. Pediatr. Transplant. 10: 570-574. *
Czaja AJ 2007 Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262.
Czaja AJ 2004 Autoimmune hepatitis: clinical and laboratory diagnosis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 52-54. *
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 2000 Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 31: 1231-1238. *
Czaja AJ, Rakela J, Hay JE, Moore SB 1990 Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 98: 1587-1593.
Czaja AJ, Rakela J, Ludwig J 1988 Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95: 448-453.
Czaja AJ, Rizzo TA, Smith WR Jr, Pruitt BA Jr 1975 Acute liver disease after cutaneous thermal injury. J. Trauma 15: 887-894.
Czaja AJ, Taswell HF, Rakela J, Schimek CM 1990 Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin. Proc. 65: 1303-1313.
D'Amico G, Luca A, Morabito A, Miraglia R, D'amico M 2005 Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 129: 1282-1293. *
Dabos KJ, Newsome PN, Parkinson JA, Mohammed HH, Sadler IH, Plevris JN, Hayes PC 2004 Biochemical prognostic markers of outcome in non-paracetamol-induced fulminant hepatic failure. Transplantation 77: 200-205.
Dahshan A 2008 Prenatal exposure to methamphetamine presenting as neonatal cholestasis. J. Clin. Gastroenterol. Jul 15 [Epub ahead of print].
Dai Y, Liang YH, Xie PY, Chen BW, Liu XG 2005 Clinical analysis of primary biliary cirrhosis: a report of 42 cases. Beijing Da Xue Xue Bao 37: 410-414.
Danielsson A, Lorentzon R, Larsson SE 1982 Intestinal absorption and 25-hydroxylation of vitamin D in patients with primary biliary cirrhosis. Scand. J. Gastroenterol. 17: 349-355.
Das KM 2004 Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294. *
Das SN, Mohapatra B, Mohanty R, Dash PC, Kar K, Dash PK 2007 Malarial hepatitis as a component of multiorgan failure - a bad prognostic sign. J. Indian Med. Assoc. 105: 247-250.
Das SS, Chaudhary RK 2007 Application of gel technology in the serologic characterization of autoantibody in DAT-positive autoimmune diseases. Immunohematol. 23: 59-62.
Davenport M, De Ville de Goyet J, Stringer MD, Mieli-Vergani G, Kelly DA, McClean P, Spitz L 2004 Seamless management of biliary atresia in England and Wales (1999-2002). Lancet 363: 1354-1357. *
Day CP 2005 Alcoholic liver disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 77. *
Day CP 2003 Alcoholic steatohepatitis (ASH). Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 85-86. October 17 - 19. *
Deems RO, Friedman LS, Friedman MI, Munoz SJ, Deems DA, Maddrey WC 1994 Relationship between liver biochemical tests and dietary intake in patients with liver disease. J. Clin. Gastroenterol. 18: 304-308.
Degos F, Degott C, Erlinger S 1980 Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis. Gastroenterol. Clin. Biol. 4: 246-250.
del Pino M, Cervio G, Dip M, Giannivelli S, Buamscha D, Ciocca M, de Davila MTG, Imventarza O, Lejarraga H 2006 Mortality risk score in liver transplantation: changes over time in its predicting power. Pediatr. Transpl. 10: 466-473. *
Delacroix DL, Reynaert M, Pauwels S, Geubel AP, Vaerman JP 1982 High serum levels of secretory IgA in liver disease: possible liver origin of the circulating secretory component. Dig. Dis. Sci. 27: 333-340.
Desai NM, Mange KC, Crawford MD, Abt PL, Frank AM, Markmann JW, Velidedeoglu E, Chapman WC, Markmann JF 2004 Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation 77: 99-106.
Deschenes M, Villeneuve JP, Dagenais M, Fenyves D, Lapointe R, Pomier-Layrargues G, Roy A, Willems B, Marleau D 1997 Lack of relationship between preoperative measures of the severity of cirrhosis and short-term survival after liver transplantation. Liver Transpl. Surg. 3: 532-537.
Desmet VJ 1995 Histopathology of cholestasis. Verh. Dtsch. Ges. Pathol. 79: 233-240.
Detry O, De Roover A, Delwaide J, Coimbra C, Kaba A, Joris J, Damas P, Meurisse M, Honore P 2004 Living related liver transplantation in adults: first year experience at the University of Liege. Acta Chir. Belg. 104: 166-171.
Dhawan A, Cheeseman P, Mieli-Vergani G 2004 Approaches to acute liver failure in children. Pediatr. Transplant. 8: 584-588.
Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G 2005 Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 11: 441-448. *
Di Campli C, Gasbarrini G, Gasbarrini A 2003 Review article: a medicine based on cell transplantation - is there a future for treating liver diseases? Aliment. Pharmacol. Ther. 18: 473-480. *
Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A 1996 Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int. J. Gynaecol. Obstet. 52: 133-140.
Diamond IR, Wales PW, Grant DR, Fecteau A 2006 Isolated liver transplantation in pediatric short bowel syndrome: is there a role? J. Pediatr. Surg. 41: 955-959.
Diaz FJ, Davalos MM, Roman VR, Bustios SC, Zumaeta VE 2004 Hepatotoxicity and pancreatitis associated with gold salts: case report. Rev. Gastroenterol. Peru 24: 353-356.
Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, Malinchoc M, Chapman RW, Kaplan MM, et al 1992 Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103: 1893-1901.
Dimmock D, Kobayashi K, Iijima M, Tabata A, Wong LJ, Saheki T, Lee B, Scaglia F 2007 Citrin deficiency: a novel cause of failure to thrive that responds to a high-protein, low-carbohydrate diet. Pediatrics 119: e773-e777. *
Ding J, Wang JL 2008 Modeling longitudinal data with nonparametric multiplicative random effects jointly with survival data. Biometrics 64: 546-556.
Ding Y, Zhao L, Mei H, Huang ZH, Zhang SL 2006 Alterations of biliary biochemical constituents and cytokines in infantile hepatitis syndrome. World J. Gastroenterol. 12: 7038-7041. *
Ding Y, Zhao L, Mei H, Zhang SL, Huang ZH, Duan YY, Ye P 2008 Exploration of Emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur. J. Pharmacol. 590: 377-386.
Ding YL, Tan LL, Deng W 2003 Clinical analysis of intrahepatic cholestasis during pregnancy in 150 patients. Hunan Yi Ke Da Xue Xue Bao 28: 645-647.
Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F 1999 Ursodeoxycholic acid treatment in children with Byler disease. Pediatr. Int. 41: 662-665.
Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H 1999 Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98.
Dixit SP 1980 Liver and the contraceptive pill. Can. J. Surg. 23: 222-227, 255.
Doise JM, Aho LS, Quenot JP, Guilland JC, Zeller M, Vergely C, Aube H, Blettery B, Rochette L 2008 Plasma antioxidant status in septic critically ill patients: a decrease over time. Fundam. Clin. Pharmacol. 22: 203-209. *
Domajnko B, Ahrendt SA 2005 Indications for non-transplant surgery in primary sclerosing cholangitis. HPB (Oxford) 7: 292-297. *
Dong YS, Huang ZH, Wu LF 1992 Treatment of infantile hepatitis syndrome with injection of yin zhi huang. Zhongguo Zhong Xi Yi Jie He Za Zhi 12: 26-27, 5-6.
Douglas JG, Beckett GJ, Percy-Robb IW, Finlayson ND 1980 Bile salt transport in the Dubin-Johnson syndrome. Gut 21: 890-893. *
Dourakis SP, Papanikolaou IS, Tzemanakis EN, Hadziyannis SJ 2002 Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur. J. Gastroenterol. Hepatol. 14: 693-695.
Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C 1995 Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J. Hepatol. 23: 674-680. *
Dubinsky MC, Fleshner PP 2003 Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200.
Dueland S, Reichen J, Everson GT, Davis RA 1991 Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem. J. 280: 373-377.
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB 2000 Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 46: 2027-2049. *
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB 2000 Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46: 2050-2068. *
Dufour JF, DeLellis R, Kaplan MM 1997 Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Intern. Med. 127: 981-985.
Dumonceau JM, Cremer M, Auroux J, Delhaye M, Deviere J 2000 A comparison of Ultraflex Diamond stents and Wallstents for palliation of distal malignant biliary strictures. Am. J. Gastroenterol. 95: 670-676. *
Edwards EB, Harper AM 2001 Application of a continuous disease severity score to the OPTN liver waiting list. Clin. Transpl. 2001: 19-24.
Ehmsen L, Marko C, Breidert M 2008 Portal vein hypertension with azathioprine therapy in patients with Crohn's disease - is it a frequent phenomenon? Dtsch. Med. Wochenschr. 133: 950-953.
Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J 2005 Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol. Immunotoxicol. 27: 77-83.
Ekdahl KN, Loof L, Nyberg A, Nilsson UR, Nilsson B 1991 Defective Fc receptor-mediated clearance in patients with primary biliary cirrhosis. Gastroenterology 101: 1076-1082.
Eken H, Ozturk H, Ozturk H, Buyukbayram H 2006 Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats. World J. Gastroenterol. 12: 5379-5383. *
El-Beshbishy HA 2008 Aqueous garlic extract attenuates hepatitis and oxidative stress induced by galactosamine/lipoploysaccharide in rats. Phytother. Res. Jun 20 [Epub ahead of print].
El-Karaksy HM, El-Hawary MI, El-Koofy NM, El-Sayed R, El-Raziky MA, Mansour SA, Taha GM, El-Mougy F 2006 Safety and efficacy of hepatitis A vaccine in children with chronic liver disease. World J. Gastroenterol. 12: 7337-7340. *
Elias E 2005 Hepatology highlights. Hepatology 42: 1241-1242. *
Ellis E, Wagner M, Lammert F, Nemeth A, Gumhold J, Strassburg CP, Kylander C, Katsika D, Trauner M, Einarsson C, Marschall HU 2006 Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J. Hepatol. 44: 243-245. *
Ellis G, Worthy E, Goldberg DM 1979 Lack of value of serum gamma-glutamyl transferase in the diagnosis of hepatobiliary disease. Clin. Biochem. 12: 142-145.
Emond JC, Whitington PF 1995 Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J. Pediatr. Surg. 30: 1635-1641.
Engelmann G, Schmidt J, Oh J, Lenhartz H, Wenning D, Teufel U, Buchler MW, Hoffmann GF, Meyburg J 2007 Indications for pediatric liver transplantation. Data from the Heidelberg pediatric liver transplantation program. Nephrol. Dial. Transplant. 22 Suppl. 8: viii23-viii28.
Enns R, Eloubeidi MA, Mergener K, Jowell PS, Branch MS, Baillie J 2003 Predictors of successful clinical and laboratory outcomes in patients with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography. Can. J. Gastroenterol. 17: 243-248.
Epstein MP, Kaplan MM 2004 A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 49: 1-4. *
Epstein O, De Villiers D, Jain S, Potter BJ, Thomas HC, Sherlock S 1979 Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N. Engl. J. Med. 300: 274-278.
Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Ryden BO, Einarsson K, Lindgren S, Wallerstedt S, Weden M 1997 Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand. J. Gastroenterol. 32: 179-186.
Eriksson S, Lindgren S 1984 The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. Scand. J. Gastroenterol. 19: 971-976.
Eriksson S, Zettervall O 1986 The N-terminal propeptide of collagen type III in serum as a prognostic indicator in primary biliary cirrhosis. J. Hepatol. 2: 370-378.
Erlinger S 1996 Mechanisms of hepatic transport and bile secretion. Acta Gastroenterol. Belg. 59: 159-162.
Ertekin V, Selimoglu MA, Orbak Z 2003 An unusual combination of relapsing and cholestatic hepatitis A in childhood. Yonsei. Med. J. 44: 939-942. *
Escobar Castro H, Garcia Novo Mf MD, Olivares P 2004 Biliary lithiasis in childhood. Therapeutic approaches. An. Pediatr. (Barc.) 60: 170-174.
Esposito I, Kubisova A, Stiehl A, Kulaksiz H, Schirmacher P 2008 Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis. Virchows Arch. Sep 4 [Epub ahead of print]. *
Etienne J, Beucler I, Ayrault M, Cloarec M, Polonovski J, Debray J 1978 Abnormal lipoproteins in a case of primary biliary cirrhosis. Biomedicine 29: 33-37.
Evenepoel P, Laleman W, Wilmer A, Claes K, Kuypers D, Bammens B, Nevens F, Vanrenterghem Y 2006 Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif. Organs 30: 276-284. *
Evenepoel P, Laleman W, Wilmer A, Claes K, Maes B, Kuypers D, Bammens B, Nevens F, Vanrenterghem Y 2005 Detoxifying capacity and kinetics of Prometheus - a new extracorporeal system for the treatment of liver failure. Blood Purif. 23: 349-358.
Ezure T, Sakamoto T, Tsuji H, Lunz JG 3rd, Murase N, Fung JJ, Demetris AJ 2000 The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am. J. Pathol. 156: 1627-1639. *
Faa G, Van Eyken P, Demelia L, Vallebona E, Costa V, Desmet VJ 1991 Idiopathic adulthood ductopenia presenting with chronic recurrent cholestasis. A case report. J. Hepatol. 12: 14-20.
Fan P, Gao T, Li M, Liao W, Fu M, Liu Y, Ikeda S 2006 A case of impetigo herpetiformis associated with intrahepatic cholestasis of pregnancy. J. Dermatol. 33: 563-566.
Fardel O, Jigorel E, Le Vee M, Payen L 2005 Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed. Pharmacother. 59: 104-114.
Farheen S, Sengupta S, Santra A, Pal S, Dhali GK, Chakravorty M, Majumder PP, Chowdhury A 2006 Gilbert's syndrome: high frequency of the (TA) (7) TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene. World J. Gastroenterol. 12: 2269-2275. *
Faybik P, Hetz H 2006 Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant. Proc. 38: 801-802. *
Feher J, Lengyel G, Blazovics A 1998 Oxidative stress in the liver and biliary tract diseases. Scand. J. Gastroenterol. Suppl. 228: 38-46. *
Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ 2005 Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42: 53-62. *
Fernandes A, Vaz AR, Falcao AS, Silva RF, Brito MA, Brites D 2007 Glycoursodeoxycholic acid and interleukin-10 modulate the reactivity of rat cortical astrocytes to unconjugated bilirubin. J. Neuropathol. Exp. Neurol. 66: 789-798.
Fernandes NF, Geller SA, Fong TL 1998 Terbinafine hepatotoxicity: case report and review of the literature. Am. J. Gastroenterol. 93: 459-460.
Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Gines P, Arroyo V 2007 Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133: 818-824. *
Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB 2004 Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 97: 407-412. *
Ferraris A, D'Amato G, Nobili V, Torres B, Marcellini M, Dallapiccola B 2006 Combined test for UGT1A1 -3279T-->G and A(TA)nTAA polymorphisms best predicts Gilbert's syndrome in Italian pediatric patients. Genet. Test. 10: 121-125.
Ferrero A, Vigano L, Polastri R, Muratore A, Eminefendic H, Regge D, Capussotti L 2007 Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J. Surg. 31: 1643-1651. *
Fevery J 2008 Bilirubin in clinical practice: a review. Liver Int. 28: 592-605. *
Fischer S, Muller I, Zundt BZ, Jungst C, Meyer G, Jungst D 2004 Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur. J. Gastroenterol. Hepatol. 16: 305-311.
Fischler B, Papadogiannakis N, Nemeth A 2001 Clinical aspects on neonatal cholestasis based on observations at a Swedish tertiary referral centre. Acta Paediatr. 90: 171-178.
Fisher L, Fisher A 2007 Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5: 513-520.
Flisiak R, Pelszynska M, Prokopowicz D, Rogalska M, Grygoruk U 2005 High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J. Gastroenterol. 11: 5706-5709. *
Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Mazzella G 2008 Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. Dig. Liver Dis. 40: 366-370.
Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Mazzella G 2006 Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment. Pharmacol. Ther. 23: 1649-1653. *
Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M 2006 Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment. Pharmacol. Ther. 24: 1051-1057.
Floreani A, Zappala F, Mazzetto M, Naccarato R, Plebani M, Chiaramonte M 1994 Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig. Dis. Sci. 39: 9-14.
Floren CH, Gustafson A 1985 Apolipoproteins A-I, A-II and E in cholestatic liver disease. Scand. J. Clin. Lab. Invest. 45: 103-108.
Flowers MT, Groen AK, Oler AT, Keller MP, Choi Y, Schueler KL, Richhards OC, Lan H, Miyazaki M, Kuipers F, Kendziorski CM, Ntambi JM, Attie AD 2006 Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diet. J. Lipid Res. 47: 2668-2680. *
Forbes A, Blanshard C, Gazzard B 1993 Natural history of AIDS related sclerosing cholangitis: a study of 20 cases. Gut 34: 116-121. *
Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, Oude Elferink RP, Housset C 2002 Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37: 184-191. *
Fox IJ 2003 Hepatocyte transplantation: clinical aspects. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper�s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 37. October 20 - 21. *
Fox IJ, Chowdhury JR 2004 Hepatocyte transplantation. Am. J. Transplant. 4 Suppl. 6: 7-13.
Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE 2008 Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin((R)), in resistant solid tumor malignancies. Cancer Chemother. Pharmacol. Apr 15 [Epub ahead of print].
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.
Freeman ML 2003 Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. Curr. Gastroenterol. Rep. 5: 145-153.
Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP 2001 Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest. Endosc. 54: 425-434. *
Fregonese L, Stolk J 2008 Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J. Rare Dis. 3: 16. *
Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC 2008 Pathophysiologic basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G1411-G1420. *
Freudenberg F, Carey MC 2005 Hepatobiliary manifestations in inflammatory bowel disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 56-57. *
Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C 1993 Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig. Dis. Sci. 38: 1291-1296.
Frezza M 1993 A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis. Ann. Ital. Med. Int. 8 Suppl.: 48S-51S.
Frezza M, Pozzato G, Chiesa L, Stramentinoli G, di Padova C 1984 Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 4: 274-278.
Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C 1990 Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 99: 211-215.
Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB 1992 Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629.
Fukui H 2005 Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure. Alcohol Clin. Exp. Res. 29: 172S-179S.
Fukumoto Y, Okita K, Kodama T, Matsuda S, Kawamura S, Harima K, Harada Y, Kawaguchi K, Iida Y, Konishi T, Andoh K, Tanaka H, Hanta T, Sekitani T, Takenami T, Yamasaki T, Yamashita S, Fujimura H, Shimada M, Kohzu M, Shigeta K, Shirasawa H 1996 Therapeutic effect of secretin in patients with jaundice; double-blind placebo-controlled multicentric trial. J. Gastroenterol. 31: 394-403.
Fukutomi T, Sakamoto S, Isobe H, Sakai H, Masumoto A, Nawata H 1992 Clinical significance of the serum levels of the 7S domain of type IV collagen in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 7: 596-601.
Fulcher AS 2004 CT cholangiography: advantages and disadvantages compared with MR cholangiography in the evaluation of the biliary tract following liver transplantation. Liver Transpl. 10: 1071-1072. *
Fung TY, Li CY 1999 Successful pregnancy in a woman with secondary biliary cirrhosis with portal hypertension from recurrent pyogenic cholangitis. A case report. J. Reprod. Med. 44: 475-477.
Furuya KN, Roberts EA, Canny GJ, Phillips MJ 1991 Neonatal hepatitis syndrome with paucity of interlobular bile ducts in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 12: 127-130.
Fusai G, Dhaliwal P, Rolando N, Sabin CA, Patch D, Davidson BR, Burroughs AK, Rolles K 2006 Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation. Liver Transpl. 12: 1626-1633. *
Galan AI, Jimenez R, Munoz ME, Gonzalez J 1990 Effects of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat. Biochem. Pharmacol. 39: 1175-1180.
Galeazzi R, Lorenzini I, Orlandi F 1980 Rifampicin-induced elevation of serum bile acids in man. Dig. Dis. Sci. 25: 108-112.
Garcia Ruiz P, Canora Lebrato J, Diez Ruiz A, Fuchs D, Wachter H 2004 Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis. Relationship with clinical severity and prognosis. Med. Clin. (Barc.) 122: 441-443.
Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J 1991 The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315.
Gardinali M, Conciato L, Cafaro C, Crosignani A, Battezzati PM, Agostoni A, Podda M 1998 Complement system is not activated in primary biliary cirrhosis. Clin. Immunol. Immunopathol. 87: 297-303. *
Garnica AD 1976 The hepatotoxicity of parenteral protein hydrolysate-containing solutions. Ann. Clin. Lab. Sci. 6: 446-454.
Geier A, Wagner M, Dietrich CG, Trauner M 2007 Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773: 283-308. *
Gennuso F, Fernetti C, Tirolo C, Testa N, L'Episcopo F, Caniglia S, Morale MC, Ostrow JD, Pascolo L, Tiribelli C, Marchetti B 2004 Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc. Natl. Acad. Sci. U.S.A. 101: 2470-2475. *
Gentile S, Persico M, Orlando C, Le Grazie C, Di Padova C, Coltorti M 1988 Effect of different doses of S-adenosyl-L-methionine (SAMe) on nicotinic acid-induced hyperbilirubinaemia in Gilbert's syndrome. Scand. J. Clin. Lab. Invest. 48: 525-529.
George R, Stevens A, Berkenbosch JW, Turpin J, Tobias J 2002 Ursodeoxycholic acid in the treatment of cholestasis and hyperbilirubinemia in pediatric intensive care unit patients. South. Med. J. 95: 1276-1279.
Georgiev P, Navarini AA, Eloranta JJ, Lang KS, Kullak-Ublick GA, Nocito A, Dahm F, Jochum W, Graf R, Clavien PA 2007 Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse. Gut 56: 121-128. *
Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL 2006 C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J. Gastroenterol. 12: 5495-5500. *
Ghibellini G, Leslie EM, Pollack GM, Brouwer KL 2008 Use of Tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm. Res. 25: 1851-1860.
Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C 2005 UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 42: 448-457. *
Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J 2007 Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13: 1106-1114. *
Glantz A, Marschall HU, Lammert F, Mattsson LA 2005 Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 42: 1399-1405. *
Glickerman DJ, Kim MH, Malik R, Lee SP 1997 The gallbladder also secretes. Dig. Dis. Sci. 42: 489-491. *
Gluud C, Brok J, Gong Y, Koretz RL 2007 Hepatology may have problems with putative surrogate outcome measures. J. Hepatol. 46: 734-742. *
Gluud C, Christensen E 2002 Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 1: CD000551. *
Goering PL 2003 The road to elucidating the mechanism of manganese-bilirubin-induced cholestasis. Toxicol. Sci. 73: 216-219. *
Goessling W, Zucker SD 2000 Role of apolipoprotein D in the transport of bilirubin in plasma. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G356-G365. *
Goldberg DM, Spooner RJ, Ellis G, Ward AM 1979 Biochemical features of intrahepatic cholestasis. Am. J. Clin. Pathol. 71: 557-563.
Gollan JL 2003 Morbus Wilson. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 91-92. October 17 - 19. *
Gong Y, Huang Z, Christensen E, Gluud C 2007 Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am. J. Gastroenterol. 102: 1799-1807. *
Gong Y, Huang ZB, Christensen E, Gluud C 2008 Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD000551. *
Goodwin B, Moore JT 2004 CAR: detailing new models. Trends Pharmacol. Sci. 25: 437-441. *
Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR 2004 Treatment endpoints for advanced cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 4-5. *
Gores GJ, Moore SB, Fisher LD, Powell FC, Dickson ER 1987 Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology 7: 889-892.
Gossard AA, Angulo P, Lindor KD 2005 Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am. J. Gastroenterol. 100: 1330-1333. *
Granato A, Gores G, Vilei MT, Tolando R, Ferraresso C, Muraca M 2003 Bilirubin inhibits bile acid induced apoptosis in rat hepatocytes. Gut 52: 1774-1778. *
Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Ferri S, Quarneti C, Cipriano V, DE Molo C, Lenzi M, Chapman RW, Bianchi FB 2007 Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment. Pharmacol. Ther. 26: 831-838. *
Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, Blesa A, Montejo JC, Garcia de Lorenzo A, Mesejo A 2007 Liver dysfunction associated with artificial nutrition in critically ill patients. Crit. Care 11: R10. *
Green RM, Flamm S 2002 AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123: 1367-1384. *
Gregory WL, Game FL, Farrer M, Idle JR, Laker MF, James OF 1994 Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 105: 43-50.
Gregory WL, Mehal W, Dunn AN, Cavanagh G, Chapman R, Fleming KA, Daly AK, Idle JR, James OF, Bassendine MF 1993 Primary biliary cirrhosis: contribution of HLA class II allele DR8. Q. J. Med. 86: 393-399.
Gresser U 2001 Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur. J. Med. Res. 6: 139-149. *
Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G 2005 Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418. *
Grivceva Stardelova K, Misevska P, Zdravkovska M, Trajkov D, Serafimoski V 2008 Total parenteral nutrition in treatment of patients with inflammatory bowel disease. Prilozi. 29: 21-43.
Grodzicki M, Pawlak J, Chrzanowska A, Porembska Z, Krawczyk M 2004 Arginase activity concentration marking in monitoring of hepatocytes function after orthotopic liver transplantation - preliminary report. Ann. Transplant. 9: 54-57.
Gruchy SE, Fardy JM 2003 A meta-analysis of ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 98: S90. *
Grune S, Mullhaupt B, Moradpour D, Munch R, Siegenthaler-Zuber G, Siegenthaler W 1991 Primary sclerosing cholangitis. Dtsch. Med. Wochenschr. 116: 1095-1100.
Grunhage F, Lammert F 2006 Pathogenesis of gallstones: a genetic perspective. Best Pract. Res. Clin. Gastroenterol. 20: 997-1015.
Gruttadauria S, Mandala' L, Miraglia R, Caruso S, Minervini MI, Biondo D, Volpes R, Vizzini G, Marsh JW, Luca A, Marcos A, Gridelli B 2007 Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin. Transplant. 21: 761-766. *
Guanabens N, Pares A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodes J 1998 Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 13: 731-738.
Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, Monegal A, Peris P, Rodes J 2005 Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J. Hepatol. 42: 573-577. *
Guastafierro S, Sessa F, Cuomo C, Tirelli A 2004 Delayed hemolytic transfusion reaction due to anti-S antibody in patient with anti-Jk(a) autoantibody and multiple alloantibodies. Ann. Hematol. 83: 307-308. *
Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O 2002 The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 49: 497-500.
Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ 2003 Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071. *
Guo L, Haga S, Enosawa S, Naruse K, Harihara Y, Sugawara Y, Irani K, Makuuchi M, Ozaki M 2004 Improved hepatic regeneration with reduced injury by redox factor-1 in a rat small-sized liver transplant model. Am. J. Transplant. 4: 879-887. *
Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M 2008 Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 121: e678-e686. *
Gylling H, Vuoristo M, Farkkila M, Miettinen TA 1996 The metabolism of cholestanol in primary biliary cirrhosis. J. Hepatol. 24: 444-451. *
Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ 2005 Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology 41: 526-534. *
Hagymasi K, Kocsis I, Lugasi A, Feher J, Blazovics A 2002 Extrahepatic biliary obstruction: can silymarin protect liver function? Phytother. Res. 16 Suppl. 1: S78-S80. *
Hallberg K, Fandriks L, Strandvik B 2004 Duodenogastric bile reflux is common in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 38: 312-316. *
Halme L, Karkkainen P, Isoniemi H, Makisalo H, von Bogulawski K, Hockerstedt K 1999 Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen. Scand. J. Gastroenterol. 34: 426-431. *
Hanada H, Okita K 1994 Primary biliary cirrhosis: therapy and prognosis. Nippon Rinsho 52: 256-261.
Handschin C, Meyer UA 2005 Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433: 387-396. *
Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Giona T, Tanaka S, Shirabe K, Shimada M, Maehara Y 2005 The newly established human hepatocyte cell line: application for the bioartificial liver. J. Hepatol. 42: 557-564. *
Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD 2001 High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 96: 1558-1562. *
Harputluoglu MM, Demirel U, Karadag N, Karahan D, Aladag M, Karincaoglu M, Hilmioglu F 2007 Severe hepatitis with prolonged cholestasis and bile duct injury due the long-term use of ornidazole. Acta Gastroenterol. Belg. 70: 293-295.
Harrison J, McKiernan J, Neuberger JM 1997 A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. Transpl. Int. 10: 369-374.
Hartmann U, Schmitt S, Reuss-Borst M 2008 Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report. Z. Rheumatol. 67: 440-444.
Harvey AM, Holt PE, Barr FJ, Rizzo F, Tasker S 2007 Treatment and long-term follow-up of extrahepatic biliary obstruction with bilirubin cholelithiasis in a Somali cat with pyruvate kinase deficiency. J. Feline Med. Surg. 9: 424-431.
Hasan MK, Tierney WM, Baker MZ 2004 Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. Am. J. Med. Sci. 328: 348-350.
Hasegawa M, Ide M, Fujita T, Takenaka S 2008 Urinary metabolic fingerprinting for alpha-naphthylisothiocyanate-induced intrahepatic cholestasis in rats using Fourier transform-ion cyclotron resonance mass spectrometry. Toxicol. Pathol. Sep 5 [Epub ahead of print]. *
Hay JE 1998 Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Liver Transpl. Surg. 4 (5 Suppl. 1): S9-S17.
Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RA, LaRusso NF 1991 The metabolic bone disease of primary sclerosing cholangitis. Hepatology 14: 257-261.
He Y, Zhang W, Tu J, Kirchheiner J, Chen Y, Guo D, Li Q, Li Z, Chen H, Hu D, Wang D, Zhou H 2008 Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the or